Skip to main content
Year archive

AstraZeneca PLC — 2023 filings

All 197 regulatory filings released by AstraZeneca PLC (AZN) in 2023, sourced directly from the official regulator.

197 Filings
2023 Period
2023 filings (197)
Filing Released Lang
ASTRAZENECA ACQUIRES GRACELL
M&A Activity
2023-12-27 English
AstraZeneca acquires Gracell
M&A Activity
2023-12-27 English
SC TO-T Filing
M&A Activity
2023-12-27 English
FORM 6-K
M&A Activity
2023-12-26 English
WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL
Regulatory Filings
2023-12-22 English
Wainua (eplontersen) granted first US FDA approval
Regulatory Filings
2023-12-22 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-12-14 English
Director/PDMR Shareholding
Director's Dealing
2023-12-14 English
FORM 6-K
M&A Activity
2023-12-12 English
ASTRAZENECA TO ACQUIRE ICOSAVAX
M&A Activity
2023-12-12 English
AstraZeneca to acquire Icosavax
M&A Activity
2023-12-12 English
SC TO-C Filing
M&A Activity
2023-12-12 English
BLOCK LISTING INTERIM REVIEW
Regulatory Filings
2023-12-01 English
TOTAL VOTING RIGHTS
Regulatory Filings
2023-12-01 English
Block listing Interim Review
Report Publication Announcement
2023-12-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-12-01 English
DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS
Regulatory Filings
2023-12-01 English
Discontinuation of two CRYSTALIZE evidence trials
Legal Proceedings Report
2023-12-01 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-11-24 English
Director/PDMR Shareholding
Director's Dealing
2023-11-23 English
TRUQAP APPROVED IN US FOR HR+ BREAST CANCER
Regulatory Filings
2023-11-17 English
Truqap approved in US for HR+ breast cancer
Regulatory Filings
2023-11-17 English
SC 13D/A
Major Shareholding Notification
2023-11-16 English
Delisting Announcement 2023
Delisting Announcement
2023-11-14 English
UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI
Regulatory Filings
2023-11-14 English
Update on PACIFIC-2 Phase III trial for Imfinzi
Earnings Release Q4 2023
2023-11-14 English
Regulatory Filings 2023
Regulatory Filings
2023-11-13 English
SC 13D
Major Shareholding Notification
2023-11-09 English
DIRECTOR DECLARATION
Director's Dealing
2023-11-09 English
IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER
Regulatory Filings
2023-11-09 English
Director Declaration
Board/Management Information
2023-11-09 English
AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA
Regulatory Filings
2023-11-09 English
9M AND Q3 2023 RESULTS
Interim / Quarterly Report 9M 2023
2023-11-09 English
Imfinzi combination improves PFS in liver cancer
Regulatory Filings
2023-11-09 English
Agreement with Eccogene for clinical stage GLP-1RA
Regulatory Filings
2023-11-09 English
9M and Q3 2023 results
Earnings Release 9M 2023
2023-11-09 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2023-11-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-11-01 English
ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS
Capital/Financing Update
2023-11-01 English
AstraZeneca cell & gene therapy deal w/ Cellectis
M&A Activity
2023-11-01 English
ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS
Legal Proceedings Report
2023-10-03 English
AstraZeneca settles Nexium liability litigations
Legal Proceedings Report
2023-10-03 English
TOTAL VOTING RIGHTS
Regulatory Filings
2023-10-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-10-02 English
DATO-DXD IMPROVED PFS IN BREAST CANCER
Regulatory Filings
2023-09-25 English
Dato-DXd improved PFS in breast cancer
Earnings Release Q3 2023
2023-09-22 English
ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT
Capital/Financing Update
2023-09-20 English
Alexion completes Pfizer gene therapy agreement
M&A Activity
2023-09-20 English
ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC
Regulatory Filings
2023-09-15 English
Enhertu recommended in EU for HER2-mutant NSCLC
Regulatory Filings
2023-09-15 English
FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT
Regulatory Filings
2023-09-11 English
Fasenra Phase III EGPA trial met primary endpoint
Regulatory Filings
2023-09-11 English
UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD
Regulatory Filings
2023-09-06 English
Update on US review of Ultomiris for NMOSD
Legal Proceedings Report
2023-09-06 English
TOTAL VOTING RIGHTS
Regulatory Filings
2023-09-01 English
Total Voting Rights
Regulatory Filings
2023-09-01 English
Delisting Announcement 2023
Delisting Announcement
2023-08-16 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2023-08-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-08-01 English
FORM 6K
Interim / Quarterly Report H1 2023
2023-07-28 English
ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER
Regulatory Filings
2023-07-28 English
Alexion enters gene therapy agreement with Pfizer
M&A Activity
2023-07-28 English
Half-year Report
Earnings Release H1 2023
2023-07-28 English
BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION
Regulatory Filings
2023-07-17 English
Beyfortus approved in US for infant RSV prevention
Regulatory Filings
2023-07-17 English
TOTAL VOTING RIGHTS
Major Shareholding Notification
2023-07-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-07-03 English
DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER
Regulatory Filings
2023-07-03 English
Dato-DXd significantly improved PFS in lung cancer
Legal Proceedings Report
2023-07-03 English
ANNUAL REPORT
Annual Report FY 2022
2023-06-28 English
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt)
Capital/Financing Update
2023-06-19 English
Group of companies' accounts made up to 2022-12-31
Annual Report
2023-06-12 English
NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION
Regulatory Filings
2023-06-09 English
ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS
Capital/Financing Update
2023-06-09 English
nirsevimab recommended for infant RSV protection
Regulatory Filings
2023-06-09 English
AstraZeneca agreement with Quell Therapeutics
M&A Activity
2023-06-09 English
IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS
Regulatory Filings
2023-06-02 English
Imfinzi improved pCR in gastric and GEJ cancers
Regulatory Filings
2023-06-02 English
BLOCK LISTING INTERIM REVIEW
Regulatory Filings
2023-06-01 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2023-06-01 English
Block listing Interim Review
Major Shareholding Notification
2023-06-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-06-01 English
LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER
Regulatory Filings
2023-06-01 English
Lynparza approved in US for BRCAm prostate cancer
Legal Proceedings Report
2023-06-01 English
IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER
Regulatory Filings
2023-05-26 English
Imfinzi + Lynparza prolonged PFS in endometrial ca
Regulatory Filings
2023-05-26 English
Delisting Announcement 2023
Delisting Announcement
2023-05-25 English
DIRECTORATE CHANGE
Board/Management Information
2023-05-22 English
Directorate Change
Board/Management Information
2023-05-22 English
TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER
Regulatory Filings
2023-05-17 English
Tagrisso plus chemo improved PFS in lung cancer
Earnings Release Q2 2023
2023-05-17 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-05-09 English
FARXIGA EXTENDED IN THE US FOR HEART FAILURE
Regulatory Filings
2023-05-09 English
Director/PDMR Shareholding
Director's Dealing
2023-05-09 English
Farxiga extended in the US for heart failure
Regulatory Filings
2023-05-09 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2023-05-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-05-02 English
ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER
Regulatory Filings
2023-05-02 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-05-02 English
Director/PDMR Shareholding
Director's Dealing
2023-05-02 English
ODAC vote on Lynparza combo in prostate cancer
Regulatory Filings
2023-05-02 English
1ST QUARTER RESULTS
Interim / Quarterly Report Q1 2023
2023-04-27 English
RESULT OF AGM
Declaration of Voting Results & Voting Rights Announcements
2023-04-27 English
Special Business Approved at AGM
AGM Information
2023-04-27 English
FORM 6-K
Regulatory Filings
2023-04-27 English
Result of AGM
AGM Information
2023-04-27 English
BOARD COMMITTEE CHANGES
Board/Management Information
2023-04-27 English
Board Committee Changes
Board/Management Information
2023-04-27 English
1st Quarter Results
Earnings Release Q1 2023
2023-04-27 English
Earnings Release 2023
Earnings Release Q1 2023
2023-04-27 English
DIRECTOR DECLARATION
Board/Management Information
2023-04-26 English
Director Declaration
Board/Management Information
2023-04-26 English
UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI
Regulatory Filings
2023-04-11 English
Update to arrangements with Sobi and Sanofi
Legal Proceedings Report
2023-04-11 English
LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER
Regulatory Filings
2023-04-05 English
Lynparza + Imfinzi met endpoint in ovarian cancer
Earnings Release Q2 2023
2023-04-05 English
TOTAL VOTING RIGHTS
Major Shareholding Notification
2023-04-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-04-03 English
ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL
Regulatory Filings
2023-04-03 English
Ultomiris recommended for NMOSD EU approval
Regulatory Filings
2023-04-03 English
ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901
Regulatory Filings
2023-03-30 English
AstraZeneca completes KYM agreement for CMG901
M&A Activity
2023-03-30 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-03-27 English
Director/PDMR Shareholding
Director's Dealing
2023-03-27 English
FORM 6-K
AGM Information
2023-03-22 English
Proxy Form for 2023 AGM
AGM Information
2023-03-22 English
Marked up version of proposed new Articles to be considered by shareholders at the Annual General Meeting on 27 April 2023
Governance Information
2023-03-22 English
Publication of proposed new Articles to be considered by shareholders at the Annual General Meeting on 27 April 2023
Governance Information
2023-03-22 English
AGM Notice of Meeting
AGM Information
2023-03-22 English
NOTICE OF AGM
AGM Information
2023-03-22 English
Notice of AGM
AGM Information
2023-03-22 English
Regulatory Filings 2023
Regulatory Filings
2023-03-15 English
8-A12B
Regulatory Filings
2023-03-13 English
IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER
Regulatory Filings
2023-03-09 English
Imfinzi improved EFS in resectable lung cancer
Earnings Release Q1 2023
2023-03-09 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-03-08 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-03-08 English
Director/PDMR Shareholding
Remuneration Information
2023-03-08 English
Director/PDMR Shareholding
Director's Dealing
2023-03-08 English
ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS
Regulatory Filings
2023-03-06 English
Enhertu DESTINY-PanTumor02 shows positive results
Regulatory Filings
2023-03-06 English
FORM 6-K
Capital/Financing Update
2023-03-03 English
Issuer Document
Capital/Financing Update
2023-03-03 English
Issuer Document
Capital/Financing Update
2023-03-03 English
424B2
Capital/Financing Update
2023-03-02 English
TOTAL VOTING RIGHTS
Regulatory Filings
2023-03-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-03-01 English
ASTRAZENECA PRICES A $2.25BN BOND OFFERING
Capital/Financing Update
2023-03-01 English
AstraZeneca prices a $2.25bn bond offering
Capital/Financing Update
2023-03-01 English
FWP
Capital/Financing Update
2023-03-01 English
424B2
Capital/Financing Update
2023-02-28 English
ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING
Capital/Financing Update
2023-02-24 English
AstraZeneca prices a EUR1.5bn bond offering
Capital/Financing Update
2023-02-24 English
ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET
Regulatory Filings
2023-02-24 English
AstraZeneca acquires CinCor for cardiorenal asset
M&A Activity
2023-02-24 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-02-24 English
Director/PDMR Shareholding
Director's Dealing
2023-02-24 English
SC TO-T/A Filing
M&A Activity
2023-02-24 English
ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901
Capital/Financing Update
2023-02-23 English
AstraZeneca PLC;AstraZeneca Finance LLC - Supplementary Prospectus
Capital/Financing Update
2023-02-23 English
AstraZeneca enters agreement with KYM for CMG901
M&A Activity
2023-02-23 English
SC TO-T/A Filing
M&A Activity
2023-02-23 English
FILING OF FORM 20-F WITH SEC
Report Publication Announcement
2023-02-22 English
Filing of Form 20-F with SEC
Report Publication Announcement FY 2022
2023-02-22 English
FORM 6-K
Regulatory Filings
2023-02-21 English
IRANNOTICE
Regulatory Filings
2023-02-21 English
FORM 20-F
Annual Report FY 2022
2023-02-21 English
ANNUAL FINANCIAL REPORT
Report Publication Announcement
2023-02-21 English
AZ 2022 Annual Report XBRL
Annual Report (ESEF) FY 2022
2023-02-21 English
AZ 2022 Annual Report XBRL
Annual Report FY 2022
2023-02-21 English
Annual Financial Report
Report Publication Announcement
2023-02-21 English
Regulatory Filings 2023
Regulatory Filings
2023-02-21 English
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-02-21 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-02-13 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing
2023-02-13 English
Director/PDMR Shareholding
Director's Dealing
2023-02-13 English
Director/PDMR Shareholding
Director's Dealing
2023-02-13 English
SC 13G/A
Major Shareholding Notification
2023-02-10 English
SC 13G/A
Major Shareholding Notification
2023-02-10 English
FINAL RESULTS
Interim / Quarterly Report FY 2022
2023-02-09 English
Final Results
Earnings Release Q4 2022
2023-02-09 English
SC TO-T/A Filing
M&A Activity
2023-02-03 English
TOTAL VOTING RIGHTS
Major Shareholding Notification
2023-02-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2023-02-01 English
UPDATE ON EVUSHELD US EUA
Regulatory Filings
2023-01-26 English
Update on Evusheld US EUA
Regulatory Filings
2023-01-26 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-24 English
SC TO-T Filing
M&A Activity
2023-01-23 English
ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED
Regulatory Filings
2023-01-17 English
Acquisition of Neogene Therapeutics completed
M&A Activity
2023-01-16 English
AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA
Regulatory Filings
2023-01-11 English
Airsupra (PT027) approved in US for asthma
Regulatory Filings
2023-01-11 English
ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET
Regulatory Filings
2023-01-09 English
AstraZeneca acquire CinCor for cardiorenal asset
M&A Activity
2023-01-09 English
SC TO-C Filing
M&A Activity
2023-01-09 English
TOTAL VOTING RIGHTS
Major Shareholding Notification
2023-01-03 English
Total Voting Rights
Regulatory Filings
2023-01-03 English